Journal profile · Psychiatry
Experimental and Clinical Psychopharmacology
ISSN 1064-1297 · eISSN 1936-2293 · American Psychological Association Inc. · UNITED STATES · Quarterly · Founded 1993
Experimental and Clinical Psychopharmacology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 1.64; hybrid open access; review 6–12 weeks (community reports); community-reported acceptance: fairly easy; 88 articles in 2025; indexed in SCIE, SSCI and Scopus.
Scope
Aims, scope and focus
Experimental and Clinical Psychopharmacology is published by American Psychological Association Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Substance Abuse Treatment and Outcomes, Neurotransmitter Receptor Influence on Behavior and Behavioral Health and Interventions, together about 33.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Experimental and Clinical Psychopharmacology ® publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, biochemistry, brain imaging, genetics, medicine, neuroendocrinology, neuroscience, and pharmacology. The overall goal of Experimental and Clinical Psychopharmacology is to provide a forum for high-quality, innovative preclinical and clinical research that advances our understanding of the behavioral and biological determinants of the effects of centrally acting drugs. More About The Journal
From the journal's Aims & Scope
Research area (LetPub): Psychiatry
Main research topics OpenAlex counts of recent articles; shares are approximate
- Substance Abuse Treatment and OutcomesMedicine12.3%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience11.4%
- Behavioral Health and InterventionsPsychology10.1%
- Smoking Behavior and CessationMedicine8.6%
- Mental Health Research TopicsPsychology5.2%
- Attention Deficit Hyperactivity DisorderMedicine5%
- Cannabis and Cannabinoid ResearchMedicine4.2%
- Child and Adolescent Psychosocial and Emotional DevelopmentPsychology3.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Psychiatry | Zone 3 |
| Minor | Psychology, Biological | Zone 3 |
| Minor | Psychology, Clinical | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Psychology, Biological | Zone 3 |
| Minor | Psychology, Clinical | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Psychiatry | Zone 4 |
| Minor | Psychology, Biological | Zone 4 |
| Minor | Psychology, Clinical | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIESSCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.64LetPub ·
- Impact factor (publisher)
- 1.6Publisher website ·
- 5-year impact factor (publisher)
- 2.5Publisher website ·
- CiteScore 2026-06
- 4.1LetPub ·
- SJR 2026-06
- 0.8LetPub ·
- SNIP 2026-06
- 0.83LetPub ·
- h-index
- 82LetPub ·
- h-index
- 131OpenAlex ·
- i10-index
- 1,494OpenAlex ·
- 2-year mean citedness
- 0.94OpenAlex ·
- Self-citation rate
- 6.2%LetPub ·
- Share of gold OA articles
- 67.03%LetPub ·
Volume
- Articles per year
- 61LetPub ·
Articles by year OpenAlex count · 2,777 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 91 | 41 | 8 |
| 2025 | 88 | 46 | 81 |
| 2024 | 86 | 46 | 161 |
| 2023 | 106 | 53 | 479 |
| 2022 | 134 | 72 | 1,049 |
| 2021 | 140 | 79 | 1,513 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- American Psychological Association Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1993
- ISSN
- 1064-1297
- Electronic ISSN
- 1936-2293
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Experimental and Clinical Psychopharmacology
What CAS zone is Experimental and Clinical Psychopharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Experimental and Clinical Psychopharmacology is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy / Psychiatry / Psychology, Biological / Psychology, Clinical. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Experimental and Clinical Psychopharmacology?
The latest impact factor listed by LetPub is 1.64; CiteScore 4.1, h-index 131.
How long does peer review take at Experimental and Clinical Psychopharmacology?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Experimental and Clinical Psychopharmacology?
According to LetPub and DOAJ records, Experimental and Clinical Psychopharmacology is indexed in SCIE, SSCI and Scopus.
Is Experimental and Clinical Psychopharmacology open access, and what is the APC?
Experimental and Clinical Psychopharmacology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .